** Island Pharmaceuticals ILA.AX jumps as much as 13.8% to A$0.165, highest since June 17
** Drug company signs asset purchase agreement to acquire Galidesivir antiviral program from BioCryst Pharmaceuticals Inc BCRX.O
** Galidesivir is a clinical-stage antiviral molecule with broad spectrum of activity in more than 20 RNA viruses, including high-priority threats such as Ebola and Marburg
** YTD, ILA down 11.8%
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.